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A B S T R A C T 
 
 
Nitrato briged dinuclear complexes of type [Cu2(L)2(bpy)2(NO3)](NO3)·4H2O, 1 and [Zn2(L)2(bpy)2(NO3)] (NO3)·4H2O, 2 
(L = deprotonated form of free ligand LH, [1-(2-hydroxyphenyl)-3-(9-anthracenyl) propenone; bpy = 2,2′bipyridine] are 
synthesized and characterized using a battery of physicochemical techniques and X-ray crystallography. A distorted square 
pyramidal geometry is assigned to them with N2O3 coordination core around the metal ion. The co-ligand L binds the metal 
ions through its O,O' atoms in anti-syn mode. The metal centers in complexes 1 and 2 are separated via bridging nitrato group 
at a distance of 6.073 Å and 5.635 Å respectively. Their structures and absorption spectra are supported by the computational 
studies using density functional theory (DFT) and TD-DFT. Both complexes exhibit nuclease activity and cleave supercoiled 
(form I) DNA. The complex 1 preferentially binds major groove of DNA and follows an oxidative pathway whereas complex 
2 binds with minor groove of DNA via hydrolytic pathway. Both complexes inhibit topoisomerase I relaxation activity with 
IC50 values of 7 and 35 ȝM. Molecular docking studies support the groove binding and topoisomerase I binding of the 
complexes. The complex 1 showed a significant cytotoxicity against HeLa cell lines (a cervical cancer cell lines) in vitro with 
IC50 value calculated as 2.9 ± 0.021 ȝM as compared to 28.2 ± 0. 044 ȝΜ for complex 2. Complex 2 induces the cell 
apoptosis at a later-stage as compared to complex 1. The cell apoptosis and topoisomerase inhibition by complexes enable 
them to be potential candidates as future anticancer drugs. 
 
 
 
 
 
 
 
 
 
1. Introduction 
 
The search for potential anticancer drugs without side eﬀ ects has always 
been demanding in drug development processes. In this context, 
cellular/molecular targets have primarily identified. Recently, the biological 
action of transition metal complexes are found capable of site specific DNA 
cleavage and DNA topoisomerase inhibition and elicited considerable interest 
for diagnostic and anti-cancer chemotherapy [1]. The site specific DNA 
cleavage by metal complexes is of contemporary interest as these complexes 
follow either oxidative or hydrolytic DNA cleavage pathways depending on 
the central metal atom and co-ordinated ligands [2]. In particular, redox 
inactive metals such as zinc 
 
[3] and zirconium [4] prefer hydrolytic cleavage mechanism, whereas redox-
active metal centers like iron and copper initiate oxidative 
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cleavage mechanism owing to the generation of reactive oxygen species 
(ROS) [5]. Oxidative damage of DNA in the presence of few ternary Cu 
 
(II) complexes is attributed to reactive hydroxyl radicals (•OH) gener-ated 
through site-specific Fenton reactions [6]. Among transition me-tals, zinc and 
copper perform various chemical, biological and medic-inal roles and are the 
second and third most abundant metal ions present in the cellular body after 
iron [7]. Copper homeostasis and metabolism are crucial to various cancerous 
cells. Moreover, Cu (II) ion can also interact with DNA through intercalation 
or surface association via N7 guanine residue of DNA [8] and it can 
significantly propagate reactive oxygen species (ROS) and subsequently 
induce DNA damage. On the other hand, Zn (II) ion being biologically 
important [9] and involved in several metalloenzymes, has recently been 
discovered to play its significant role in tumor suppression [10]. In this 
  
 
dinuclear and multinuclear complexes are found to possess synergistic eﬀ ect 
as compared to their corresponding mononuclear analogues in terms of DNA 
binding, cleavage, cytotoxicity and their cellular uptake [11,12]. Recently, 
Spingler et al. reported that dinuclear Cu(II) and Ni 
 
(II) complexes containing 1,3-bis(1,5,9-triazacyclododecyl) propane, change 
the conformation of right handed B-DNA into left-handed Z-DNA, but their 
analogous mononuclear complexes could not induce such conformational 
changes [13]. On the other hand, Khalil et al. described the presence of an 
oxolating source in dinuclear curcu-min–metal complexes (Zn and Cu). They 
inhibited the synergistic eﬀ ect by pre-exhaustion of curcumin reducing 
potential eﬀ ect of cytotoxic activity against four cancer cell lines [14]. Thus, 
the design and synthesis of dinuclear complexes especially of Cu(II) and 
Zn(II) was found interesting. The tuning to highly eﬃcient anticancer drugs 
which could regulate metal uptake, traﬃcking, function and excretion in 
biological systems and provide better activities in drug resistance cells [15] 
requires a proper manipulation of both the metal ions and ligand frameworks. 
A suitable anionic linker or template eﬀ ects have been successfully exploited 
as the most eﬀ ective tools in the direct synthesis of dinuclear complexes. 
Anions do not function only to balance the charge in metallorganic hybrid 
species, but they also play a crucial role in creating structural versatility by 
bridging the components together and provide structures of higher 
dimensionality and also stabilize their structures. For example, the planar 
anions such as NO3− and CO32– originate supramolecular networks together 
with cyclic structures [16,17]. The nitrato ligand (NO3−), which behaves as 
monodentate or a bidentate chelating agent [18] particularly shows the ȝ-
(O,O′)-bridging mode in its copper(II) complexes. On the other hand, nitrate 
represents very common bridging ligand acting through diﬀ erent coordination 
modes [19] yet structural and biological studies of metal complexes bridged 
by nitrate are scarce. Thus, based on such precedence, and in view of 
remarkable DNA binding, cleavage and cytotoxicity [20,21] exhibited by 
copper bipyridine complexes planar aromatic organics species such as 2,2′ 
bipyridine was selected as a ligand. The selectivity of a hydroxyl chalcone 
embedded with a conjugated anthracenyl fra-meworks as ligand was also 
considered important owing to its phar-maceutical importance [22] and ability 
to act as bidentate O,O' donor which may probably involve in the construction 
of H-bonded networks in view of our earlier report [23,24]. Thus, in 
anticipation of some new unprecedented structural frame works, it was 
thought worthwhile to condense a chalcone LH (protonated form of L) 
separately with Cu(bpy) (NO3)2·H2O and Zn(bpy)(NO3)2·H2O. As expected, 
such reactions al-lowed to generate new rare homodinuclear complexes 
containing Cu (II)-Cu(II) and Zn(II)-Zn(II) metal centers bridged via nitrato 
groups in each case. We further investigated these nitrato bridged dinuclear 
complexes for their applications in DNA cleavage studies. The structural 
tunability of metal complexes was also considered as a beneficial fea-ture to 
exploit this framework in cytotoxicity and apoptotic studies. 
 
 
 
 
2. Experimental Section 
 
2.1. Materials and Methods 
 
Dinitrato trihydrate salt of Cu(II) and dinitrato hexahydrate salt of 
Zinc(II), 2,2′-bipyridine, and 9-anthracenaldehyde were purchased from 
Sigma Aldrich Chem. Co. and used as received without further purification. 
The solvents were purchased from E. Merck and were freshly distilled prior to 
their use. IR (KBr disc, 400–4000 cm−1) spectra were recorded on a Varian 
FTIR 3100 spectrometer; elemental analysis was carried out using Carbo-
Erba 1108 elemental analyzer, UV-visible (UV-vis) were recorded on a Jasco 
V-630 spectrometer. However, 1H NMR spectra were recorded in DMSO‑d6 
using JEOL AL 300 MHz spectrometer and TMS was used as internal 
reference. ESI-MS measurements were performed by using a Waters Q-TOF 
Premier mass spectrometer. ESR spectrum of Cu(II) complex was recorded at 
273 K and 77 K on a Varian E-line Century Series ESR spectrometer 
equipped 
 
 
with a dual cavity and operating at X-band of 100 kHz modulation frequency. 
Tetracyanoethylene was used as the field marker (g = 2.00277). 
 
2.2. X-ray Structural Studies 
 
Single crystal X-ray diﬀ raction data of the ligand and complexes were 
collected in the temperature range of 293(2) K and 150(2) K using an Oxford 
diﬀ raction XCALIBUR-S CCD area detector diﬀ ractometer and graphite 
monochromatized Mo Kα radiation (Ȝ = 0.71073) from needle shaped crystals 
in ω–2θ scan mode for all the complexes. Intensities of these reflections were 
measured periodically to monitor crystal decay. The crystal structures were 
solved by direct methods and refined by full matrix least squares (SHELX-97) 
[25]. Due to high de-gree of hydration, thermal motion and disorder, 
hydrogen atoms of water of crystallization could not be located. Drawings 
were carried out using MERCURY [26] and special computations were 
carried out using PLATON [27]. The precursor complexes of type M(2,2′-
bipy) (NO3)2·H2O (M = Cu(II), Zn(II))were prepared and characterized using 
reported procedure [28]. 
 
 
2.3. Synthesis of Ligand 1-(2-hydroxyphenyl)-3-(9-anthracenyl)propenone 
(LH) 
 
The ligand 1-(2-hydroxyphenyl)-3-(9-anthracenyl)propenone (LH) was 
synthesized by the condensation of 2′-hydroxy acetophenone and 9-
anthracenaldehyde in the presence of 50% NaOH solution using a method 
reported earlier [29]. Yield: 226 mg (70%), M.P. 166 °C, IR (KBr pellet, 
cm−1): 2924(m) υ(CeH), 1634(s) υ(C]O), 1299(s) υ(OeH); 1H NMR 
(CDCl3,į ppm): 12.85(s, 1H, eOH), 6.88–8.93 (m, 13H, Ar), 7.70 (d, 1H, 
Hα), 6.91 (d, 1H, Hȕ), 13C NMR (CDCl3, į ppm): 193.19 (C]O) 163.83 
(AreCO), 142.66 (C-α), 125.12 (C-ȕ),118.69, 
118.99, 125.48, 126.62, 128.78, 128.98, 129.37, 129.67, 129.75, 
 
129.88, 131.28, 136.64 (eAr), UV-vis (methanol, 10−4 M): Ȝmax(nm) (İmax × 
104 M−1 cm−1) 251 (3.638), 352(0.7377), 425 (1.0915), 
 
Ȝemission 511 nm at Ȝexcitation 424 nm. 
 
2.4. Synthesis of Complex [Cu2(L)2(bpy)2(NO3)](NO3)·4H2O 1 
 
A methanolic solution (20 mL) of Cu(bpy)(NO3)2·H2O (0.361 g, 1 mmol) 
was added drop wise to a solution of LH (0.324 g, 1 mmol) in 
dichloromethane (5 mL). The reaction mixture was initially stirred for 12 h 
then refluxed for another 2 h. The resulting solution was then kept in a 
refrigerator. After 5–6 days, the brown colored needle shaped crystals were 
obtained. These crystals were washed with diethyl ether and dried in air. 
Yield: 0.503 g(40%), M.P. > 230 °C, elemental ana-lysis calculated for 
C66H54N6O14Cu2 (%): C 61.82; H 4.24; N 6.55, Found: C, 61.45; H, 4.68; 
N, 6.64. ESI-MS: (m/z) calcd.: 1146 found: 1147 [M]+. IR (KBr): Ȟmax/cm−1 
3436 (OH, H2O), 2926(m) υ(CH, Ph), 1616 υ(CO, 2,2′-bpy), and 1382, 
1243υ(NO3, ȝ1,3-bridging nitrate). UV-vis. absorptions: Ȝmax (methanol, 
10−4 M)/nm (İ × 10−4/M−1 cm −1) 295 (3.01), 306 (3.08), 454 (2.93) and 657 
(0.0389) Ȝemission, 526 nm at Ȝexcitation 454 nm. 
 
2.5. Synthesis of Complex [Zn2(L)2(bpy)2(NO3)](NO3)·4H2O 2 
 
A solution of Zn(bpy)(NO3)2·H2O (0.363 g, 1 mmol) in methanol (20 
mL) was added dropwise to a solution of LH (0.324 g, 1 mmol) in DCM (5 
mL) with stirring at room temp. The stirring was further con-tinued up to 12 h 
then the solution was refluxed for 6 h. After cooling the reaction mixture, 
methanol (10 mL) was added to it and the solu-tion was stored in a 
refrigerator. After 5–6 days, the light yellow needle shaped crystals were 
obtained. These crystals were washed with me-thanol and dried in air. Yield: 
0. 435 g (34%), M.P. > 230 °C, elemental analysis calculated for 
C66H54N6O14Zn2 (%): C, 61.65; H, 4.23; N 6.54, Found: C, 61.98; H, 4.59; 
N, 6.78. ESI-MS: (m/z) calcd.: 1171 found: 
 
 
  
 
1171 [M + Na-H]+. IR (KBr): Ȟmax/cm−1 3446 (OH, H2O), 2916(m) υ(CH, 
Ph), 1619 υ(CO, 2, 2′-bpy), and 1383, 1245 υ(NO3−, ȝ1,3-brid-ging nitrate). 
1H NMR: (DMSO‑d6, į ppm) 8.04–8.32(16H, m, bpy), 
 
7.03–8.71 (m, 26H, Ar), 8.33 (m, 2H, Hα), 6.96 (m, 2H, Hȕ). 13C NMR: 
(DMSO‑d6, į ppm) 168.29 (C]O), 170.87 (AreCO), 143.21 (C-α), 122.45 (C-
ȕ), 149.05, 135.62, 123.42 (bpy), 135.43, 133.07, 132.22, 
131.16, 129.12, 128.89, 128.72, 127.45, 126.76, 125.42, 125.67, 
125.46, 115.12 (Ar); UV-vis absorptions: Ȝmax (methanol, 10−4 M)/nm (İ × 
10−4/M−1 cm−1) Ȝmax 250 (2.59), 274 (1.25), 313 (1.27) and 458 (1.29). 
Ȝemission, 538 nm at Ȝexcitation 458 nm. 
 
2.6. Electrochemical Studies 
 
Cyclic voltammetry was performed on a CHI 620c electrochemical 
analyzer. A glassy carbon working electrode, platinum wire auxiliary 
electrode, and Ag/Ag+ reference electrode were used in a standard three-
electrode configuration. Tetrabutylammoniumperchlorate (TBAP) was used as 
a supporting electrolyte, and the solution con-centration was kept as 10−3 M. 
 
2.7. DNA Cleavage Studies Using Agarose Gel Electrophoresis 
 
In the gel electrophoresis experiments, supercoiled pBR322 DNA was 
treated separately with metal complexes, and the mixture was in-cubated for 1 
h at 37 °C. The samples were then analyzed by 1% agarose gel 
electrophoresis [Tris − acetic acid − ethylenediaminetetraacetic acid (EDTA) 
(TAE) buﬀ er, pH 8.3] for 2 h at 50 V. The gel was stained with 0.5 ȝg mL−1 
ethidium bromide, visualized by UV light, and pho-tographed for analysis. 
The extent of cleavage of form I (SC) DNA was determined by measuring 
intensities of the bands using a Genosens 1510 Gel Documentation System. 
The experiments was also monitored on addition of various activators, viz., 
NaN3, D2O (1O2 singlet oxygen trapper), sodium formate, DMSO, KI (•OH 
radical scavenger), sodium ascorbate (reducing agent) and H2O2 (oxidizing 
agent). 
 
2.8. Topoisomerase Inhibition Assay 
 
DNA topoisomerase I (Topo I) from Escherichia coli was purchased from 
New England Biolabs, and no further purification was performed. One unit 
(U) of the enzyme was defined as the amount that completely relaxed 0.5 ȝg 
of negatively charged supercoiled pBR322 plasmid DNA in 30 min at 30 °C 
under standard assay conditions. The reaction mix-ture (15 ȝL) consists of 50 
mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium acetate, 1 
mM DTT (dithiothreitol), 0.1 mg/mL BSA, and 1 U of Topo I together with 
variable concentration of com-plexes 1 and 2 (0–25 ȝM and 0–50 ȝM 
respectively) and 0.5 ȝg of pBR322 DNA. The corresponding reaction 
mixtures were incubated at 37 °C for 1 h, and then they were terminated by 
the addition of 3 ȝL of 5 × stock solution of dye consisting of 0.25% 
bromophenol blue, 4.5% sodium dodecyl sulfate, and 45% glycerol. The 
electrophoresis of the samples was carried out through 1% agarose in TAE 
buﬀ er at 50 V for 2 h. The gel was stained with 1 ȝg mL−1 EB and 
photographed under UV light. The concentration of the inhibitor that 
prevented 50% of the supercoiled DNA being converted into relaxed DNA 
(IC50 values) was calculated from the midpoint concentration of the complex-
induced DNA unwinding. To check whether order of addition aﬀ ected the re-
sults, experiments were also carried out in ice, in which the whole re-action 
mixture was assembled. 
 
 
2.9. Molecular Docking Methodology 
 
The molecular docking is an interactive molecular graphics program to 
calculate and display feasible docking modes of a pair of protein, enzymes 
and DNA molecule. The molecular docking studies have been performed by 
using Autodock Vina version 1.1.2.29 [30,31]. All rota-table bonds within the 
ligand were allowed to rotate freely and receptor 
 
 
was considered rigid. The crystal structure of the B-DNA dodecamer d 
(CGCGAATTCGCG)2 (PDB ID: 1BNA) was retrieved from the protein data 
bank (http://www.rcsb.org./pdb). Visualization of docked systems have been 
performed using Discovery studio 4.1 and PyMol.30 [32,33]. 
 
2.10. MTT Assay 
 
HeLa cells were grown in Dulbecco's Modified Eagle's medium (DMEM) 
supplemented with 10% (vol/vol) FBS and maintained at 37 °C in a 
humidified atmosphere of 5% CO2. The cells (1 × 104) seeded in 96-well 
plate and grown overnight were treated with diﬀ erent concentration of crude 
extract at 24 h. Four hours prior to completion of treatment duration, cultures 
were supplemented with MTT. After incubation at 37 °C, the cells were lysed 
with dimethyl sulfoxide and absorbance was measured at 570 nm using 
ELISA plate reader. The percentage of cell viability was calculated using the 
following formula: Percentage cell viability = (OD of the experiment 
samples/OD of the control) × 100. IC50 was calculated by linear interpolation 
method. 
 
2.11. Apoptosis: Acridine-orange/EtBr Staining Protocol for HeLa Cells 
 
The cells (1 × 105) were grown in cover slip and treated with 65 ȝM of 
LH, 2 ȝM of complex 1 and 25 ȝM of complex 2 for 24 h. Cells were washed 
in 1× PBS. Cells were stained with 100 ȝL of (from stock 100 ȝg/mL) of 
EtBr for 2.5 min and again stained with 20 ȝL of acridine orange (100 
ȝg/mL) for 1 min. Cells were washed twice in PBS and suspended in 500 ȝL 
PBS. Image was taken from Nikon90i Eclipse fluorescence microscope. 
 
 
3. Result and Discussion 
 
3.1. Synthesis and Characterization 
 
Dinuclear complexes 1 and 2 were prepared by the reaction of LH 
separately with Cu(bpy)(NO3)2·H2O and Zn(bpy)(NO3)2·H2O. The IR 
spectrum of free LH displayed peaks at 1634 and 1579 cm−1 assigned to 
υas(C]O) and υs(C]O) vibrations respectively. Corresponding peaks were 
shifted at 1619, 1549 cm−1 and 1617, 1547 cm−1 in the spectra of 1 and 2 
respectively. This observation supported the coordination of C]O group of LH 
to the metal ion. The bands observed at 1382, 1243 cm−1 and 1382, 1245 
cm−1 in the spectra of 1 and 2 were as-signed to υas (ȝ1,3-bridging nitrate) 
and υs(ȝ1,3-bridging nitrate) re-spectively in view of earlier report [34]. No 
peak for υs(OH) vibration was observed in the spectra of both complexes. It 
was therefore, con-sidered that deprotonated OH group of LH had 
coordinated to the metal ion. The υ(bpy) vibration appeared at 1619 and 1623 
cm−1 in the spectrum of 1 and 2 respectively. Additional broad band 
observed at 3436 and 3446 cm−1 in the spectrum of respective complexes was 
as-signed to υ(OH) of water molecules. 
 
The 1H NMR spectrum of complex 2 displayed peaks at į(ppm) 8.33 (m, 
2H, Hα), 8.04–8.32 (16H, m, bpy), 7.03–8.71 (m, 26H, Ar), 6.96 (m, 2H, 
Hȕ). Since no peak corresponding to OH proton was observed in the spectrum 
of the complex 2, it again supported that deprotonated OH group had 
coordinated with Zn(II) ion. A downfield shift of ethylenic protons could be 
understood as a consequence of the coordination of neighboring C]O group 
[35]. The ESI-MS (S1) of complexes recorded in acetonitrile-water showed 
molecular ion peak at m/z 1147 and 1171 assigned to [M]+ and [M + Na-H]+ 
for complexes 1 and 2 respec-tively. 
 
 
3.2. Photophysical Properties 
 
The electronic absorption spectra of the complexes and LH recorded in 
methanol are displayed in Fig. 1(a). The spectrum of LH showed three peaks 
at Ȝmax 251, 352 and 425 nm. The longer wavelength ab-sorption could be 
assigned to intramolecular charge transfer (ICT) 
 
 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. (a) UV–vis spectra (b) Emission Spectra of LH, Complex 1 and 2 recorded in methanol. 
 
where as high energy peaks originate from π → π* transition in con-sistence 
with earlier report [36]. In the absorption spectrum of complex 1, four peaks 
displayed at Ȝmax 295, 306, 454 and at 657 nm were as-signed to ligand 
centered (LC) π → π*(bpy), intraligand charge transfer transition (ILCT), 
O(L) → CuII transition and d-d transitions respec-tively. Normally, a typical 
square pyramidal complex displays d-d transition band between Ȝmax 550–
650 nm [37]. Therefore, a distorted square pyramidal geometry was assigned 
to complex 1. Absorption spectra of the complexes recorded in methanol at 
25 °C for 0–48 h also supported that they are retained in the solution (S2). 
The complex 2 also displayed similar peaks at Ȝmax 250, 274, 313 and 458 
nm. The photophysical properties of substituted chalcones involve mostly 
asymmetrical donor-acceptor-chalcones and to a minor extent symme-trical 
donor-acceptor-donor-chalcones in which the acceptor part is the carbonyl 
group whereas substituted phenyl group serves as donor part [38]. A 
luminescence peak is observed at Ȝemission 511 nm from free ligand (LH) on 
excitation of its solution in methanol (10−4 M) at Ȝex = 425 nm and is 
depicted in Fig. 1(b). The intrinsic probes are usually designed as donor-
acceptor substituted π-systems, and their excited-state behavior is usually 
governed by an intramolecular charge transfer (ICT) process [39]. In view of 
this report, anthracenyl group present in the chalcone skeleton can act as 
electron-donor where as its carbonyl group may act as electron-acceptor. 
Therefore, in present chalcone system, excited state could also be attributed to 
an in-tramolecular charge transfer process [40] On excitation at Ȝex = 454 nm, 
weak emission from complex 1 was observed at Ȝmax, 526 nm while complex 
2 emitted at 538 nm when excited at Ȝex 
 
 
458 nm. Since, copper (II) complexes do not exhibit emission as Cu(II) ion is 
well known quencher [41], the weak emission from complex 1 could be 
assigned to ligand centered emission only. However, sig-nificant emission 
arising from Zn(II) complex could also be contributed by the emission arising 
from terminal ligand (bpy). The luminescence from free LH is reduced by 
~60% and ~ 26% in its complexes 1 and complex 2 respectively. Emission 
spectral traces for the complexes in methanol were also recorded at 25 °C for 
0–48 h and do not show any significant spectral changes in solution (S3). 
 
 
3.3. Structural Discussion 
 
Since, single crystal X-ray structural analysis of LH is not reported till 
today therefore its molecular structure is studied and shown in Fig. 2(a). The 
ligand LH crystallized from dichloromethane: petroleum ether (1:3) provides 
monoclinic crystal system with a space group P21/ c. The bond length 
between O(3)eC(017) and O(4)eC(035) was found as 1.245(2) Å and 
1.342(2) Å respectively. However, bond length be-tween C(008)eC(023) as 
1.405(2) Å was found closer to the value as reported for aromatic ring system 
[42]. It was observed that CeH and C]O groups are involved in hydrogen 
bond formation, the motifs C020eH020…O3 and C034eH034…O1 contacts 
with HeO at a dis-tance of 2.7934 Å and 2.8121 Å respectively. This H-
bonded net-work resulted in a supramolecular structure as depicted in Fig. 
2(b). 
 
The structures of complexes 1 and 2 were investigated using their X-ray 
crystallography and data are listed in Table 1. Their molecular structures 
showed that both metal ions are bridged by a nitrato ion in 
 
Fig. 2. (a) Molecular structure of LH (b) 
 
Scorpion like Supramolecular structure of 
 
LH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 1 
 
Data collection and structure refinement parameters for LH, complexes 1 and 2. 
 
 
Parameters LH 1 2 
    
Chemical 
C
23
H
16
O
2 
C
66
H
46
N
6
O
14
Cu
2 
C
66
H
52
N
6
O
14
Zn
2 
formula    
Formula weight 324.36 1274.19 1283.92 
Temperature 293(2) K 150(2) K 150(2) K 
Wavelength (Å) 0.71073 0.71073 0.71073 
Crystal system Monoclinic Monoclinic Monoclinic 
Space group P21/c P121/c1 P121/c1 
a(Å) 14.1054(5) 14.5876(6) 13.9836(2) 
b(Å) 13.9243(5) 22.9903(9) 23.4802(7) 
c(Å) 17.2620(6) 16.9884(5) 17.4585(4) 
α(°) 90 90 90 
ȕ(°) 101.672(4) 96.109(3) 96.988(3) 
Ȗ(°) 90 90 90 
Volume (Å3) 3320.3(2) 5665.1(4) 5689.7(2) 
Z 8 4 4 
Absorption 0.082 0.828 0.920 
coeﬃcient    
F(000) 1392 2616 2648 
Theta range for 2.08 to 26.81 3.29 to 25.00° 3.40 to 23.04 
data    
collection    
Reflections 11,914/6531 [R 42,758/9953 [R 34,805/7605 [R 
collected/ (int) = 0.0196] (int) = 0.0961] (int) = 0.0772] 
unique    
Completeness to 98.3% 99.7% 95.6% 
theta    
Goodness-of-fit 1.025 0.916 0.837 
on F2    
Final R indices R1 = 0.0503, R1 = 0.0609, R1 = 0.0514, 
[I > 2ı(I)] wR2 = 0.1187 wR2 = 0.1608 wR2 = 0.1228 
R indices (all R1 = 0.0952, R1 = 0.1217, R1 = 0.0913, 
data) wR2 = 0.1295 wR2 = 0.1773 wR2 = 0.1324 
    
 
corresponding complexes as depicted in Fig. 3(a) and (b). Although nitrate 
bears diversified modes of coordination [43] yet nitrato bridged complexes are 
rare [44]. Bridging of nitrato group as anti-syn bridge-bonding bidentate 
mode could probably arises from imposition of the bulky anthracenyl group 
present in the skeleton of the chalcone ligand. The complex 1 crystallized as a 
monoclinic crystal system with P121/c1 as space group. Its structure consists 
of a cationic dinuclear molecular unit in which oxygen atoms of nitrate group 
bridged to two Cu(II) centers. Each Cu(II) ion is penta-coordinated consisting 
of N2O3 co-ordination core. In view of earlier report [45] a distorted square 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Molecular structure of (a) complex 1, (b) complex 
 
 
pyramidal geometry of complex 1 is supported by Ĳ = 0.183, [Ĳ = |ȕ- 
 α |/60°] value, where ȕ and α are the two largest angles around the central 
atom. The bridging nitrato group is involved in anti-syn bridge-bonding mode 
with two copper atoms bound to diﬀ erent oxygen atoms of the nitrate ion. 
The atoms O1, O2, N1 and N2 occupy the basal plane of the square pyramid 
whereas O3 atom occupies the apical position. The CueN and CueO 
distances are found in the reported range S4 [46]. The Cu(II) ions are 
separated by an intramolecular distance of 6.073 Å (Cu1……Cu2) and found 
lower in comparison to earlier reported ni-trato bridged complex most likely 
owing to the presence of bulky an-thracenyl group present in chalcone moiety 
[47]. The molecular asso-ciation through non-covalent interaction provides an 
interesting supramolecular network of helical chains as depicted in S5. 
Several H-donor and H-acceptor functional groups present in the skeleton of 
the chalcone form twelve hydrogen bonds S6. The non-conventional hy-
drogen bonds involve CeH as H-donor and oxygen as H-acceptor. It has a 
Kitaigorodskii Packing Index (KPI) of 68.9% which shows compact packing 
with few solvent accessible voids. The structure of complex 1 was also 
supported by its ESR spectra recorded in solid state as well as in solution 
(methanol) at room temperature and at liquid N2 tempera-ture and are shown 
in [S7]. 
 
The coordination environment around Zn(II) was found similar to that of 
complex 1. The complex 2 was crystallized as monoclinic with space group 
P121/c1. Each symmetric unit contains [Zn(L)(bpy)] bridged via nitrate anion 
resulting in a centrosymmetric dinuclear building block along with four co-
crystallized water molecules. Each Zn (II) ion is bonded to two N atoms of 
2,2′ bipyridyl group and two oxygen atoms from L in an anti-syn fashion. The 
ZneN (2.086(4) Å) and ZneO (1.993(3) Å) distances are found similar to that 
found for re-ported Zn(II) complexes [48]. Both Zn(II) ions are surrounded by 
a distorted square-pyramidal geometry with Ĳ value = 0.133 having C4V 
symmetry. The bpy and chalcone groups are almost perpendicular to the 
nitrate plane. Two Zn(II) chalcone-bpy units are bridged via a ni-trato group 
and lie parallel to each other leading to the formation of H-shaped 
supramolecular structure S8. 
 
Interestingly, two H-shaped supramolecular complexes intersect to each 
other and form a chair shaped structure Fig. 4(a). There is a two-fold 
symmetric axis (C2) along b direction, leading to chirality within the 
structure. The intermolecular centroid–centroid distance between two Zn(II) 
ions are at 5.635 Å. There are twelve non-conventional H-bonds formed in 
the packing of this complex. The co-crystallized water molecules together 
with nitrato group are forming a channel like structure as depicted in Fig. 
4(b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Hydrogen atoms are omitted for clarity in complex 1 and 2. 
 
 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. (a) Chair form structure of complex 2. (b) Channel like structure of complex 2 formed using water and nitrate anion. 
 
Computational data as shown in S9 were calculated using density 
functional theory (DFT) and TD-DFT and supported the experimentally 
observed structures and absorption spectra of both complexes. 
 
3.4. Cyclic Voltammetry 
 
To understand the redox processes of complex 1, its cyclic voltam-metry 
(S10) was recorded in DMF at 298 K using ferrocene/ferrocenium (Fc/Fc+) as 
an internal standard (0.10 V (80 mv) vs Ag/Ag+) in +1 to 
 
+ 2.0 V ranges. Complex 1 showed irreversible reduction and oxidation 
peaks. The cyclic voltammogram of the complex 1 displayed two cathodic 
potentials at −0.52 V and −1.33 V which were assigned to the reduction peaks 
of coordinated L. The bimetallic CueCu complex showed reduction of two 
Cu(II) ions at 0.85 V and 1.04 V. The oxidation peak observed at 0.85 V is 
assigned to the oxidation of copper [49]. 
 
3.5. Interaction of the Complexes With DNA Using DNA Gel Electrophoretic 
Mobility Assay 
 
For the anticancer drug development, the fine tuning of metal complexes 
that bind and cleave DNA with structural selectivity has gained interest. The 
ability of complexes to cleave DNA is usually as-sessed by agarose gel 
electrophoresis of supercoiled plasmid DNA under physiological conditions. 
The gel electrophoretic mobility assay of DNA determines alteration of DNA 
structure by retardation in migration of supercoiled (Form I) plasmid DNA to 
nicked circular form (Form II) and to open circular relaxed form (Form III) of 
DNA using synthetic metal complexes. In order to assess the chemical 
nuclease activity, pBR322 DNA was incubated with varying concentrations 
of complexes 1 and 2 (0–50 ȝM) separately in tris buﬀ er for 1 h. The 
mobility graphs are shown in Figs. 5(a and b) and 6(a and b). The complex 1 
converts > 50% of form I into form II at a concentration of 30 ȝM, whereas, 
for a similar level of conversion, ~35 ȝM of complex 2 was required. It 
suggested that Cu(II) complex 1 significantly cleaved DNA as compared to 
that of Zn(II) complex. 
 
 
3.6. DNA Cleavage in Presence of Groove Binders 
 
In order to identify the potential interacting site of the complexes with 
supercoiled plasmid pBR322 DNA, gel electrophoretic mobility assay was 
performed in presence of both minor groove binding agent 4′,6-diamidino-2-
phenylindole (DAPI) and major groove binding agent, methyl green (MG). 
The supercoiled DNA was treated with DAPI and MG prior to the addition of 
complexes 1 and 2 even in lower con-centration (20 ȝM). As depicted in Fig. 
7 in presence of complex 1 and MG, form I DNA is completely converted in 
form II and form III DNA. However, form I DNA is completely converted in 
form II and form III DNA in presence of complex 2 together with DAPI. This 
experiment supported that complex 1 has a tendency of binding with the 
major groove of DNA whereas complex 2 prefers minor groove of DNA. 
 
 
3.7. Investigation of DNA Cleavage in Presence of Activator and Radical 
Scavengers 
 
The nuclease mechanism could be inferred by monitoring the quenching 
of DNA cleavage in the presence of various radical sca-vengers such as 
singlet oxygen trapper (NaN3, D2O), both oxidizing and reducing agent 
(H2O2),•OH radical scavenger (sodium formate, KI, DMSO) and reducing 
agent (sodium ascorbate). Complex 1 in the pre-sence of sodium formate and 
DMSO as a hydroxyl radical scavenger and sodium ascorbate as reducing 
agent did not cleave eﬃciently under identical conditions as depicted in S11. 
The possibility of singlet oxygen (1O2) pathway was discarded owing to 
cleavage of DNA in the presence of activator NaN3 and also in D2O (singlet 
oxygen trapper). The com-plex 1, in the presence of H2O2 converted from I 
form to II form of DNA even at lower concentration (20 ȝM). Therefore, 
DNA cleavage pro-moted by the complex 1 might occur via an oxidative 
pathway [20]. No evident inhibition of DNA cleavage by complex 2 was 
observed in the presence of scavengers such as NaN3, D2O and H2O2 which 
suggested that DNA cleavage promoted by it follows neither singlet oxygen 
(1O2) pathway nor oxidative pathway “see Fig. S12 in Supplementary 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Ethidium bromide stained agarose gel (1%) of pBR322 plasmid DNA (300 ng ȝL−1) in the presence of complex 1 after 1 h of incubation: lane 1, DNA control; lane 2, pBR322 + 10 ȝM; lane 
3, pBR322 + 20 ȝM; lane 4, pBR322 + 30 ȝM; lane 5, pBR322 + 40 ȝM; Lane 6, pBR322 + 50 ȝM (b) Cleavage of supercoiled pBR322 DNA showing the decrease in Form I DNA and the 
formation of Form II DNA with increasing concentration of complex 1. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Ethidium bromide stained agarose gel (1%) of pBR322 plasmid DNA (300 ng ȝL−1) in the presence of complex 2 after 1 h of incubation: lane 1, DNA control; lane 2, pBR322 + 10 ȝM; lane 
3, pBR322 + 20 ȝM; lane 4, pBR322 + 30 ȝM; lane 5, pBR322 + 40 ȝM; Lane 6, pBR322 + 50 ȝM (b) Cleavage of supercoiled pBR322 DNA showing the decrease in Form I DNA and the 
formation of Form II DNA with increasing concentration of complex 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Agarose gel electrophoresis pattern of pBR322 plasmid DNA (300 ng) by the 
complexes (20 ȝM). Lane 1, DNA control; Lane 2, DNA + complex 1 + DAPI; Lane 3, DNA + 
complex 1 + methyl green; Lane 4, DNA + complex 2 + DAPI; Lane 5, DNA + complex 2 + 
methyl green. 
 
 
material”. There are several reports that dinuclear metal ion sites may 
hydrolyze phosphate esters and RNA by double Lewis acid activation with 
one metal ion binding to the incoming nucleophile, the second metal ion 
binding to the leaving group, and both metal ions binding to the 
phosphatediester [50]. The complex also showed similar kind of hydrolytic 
mechanism as observed in crowded phenolate type com-plexes such as 
quercetin zinc(II) complex [51]. So, it concluded that complex 2 might be 
following a hydrolytic pathway. 
 
3.8. Topo I Inhibition Assay 
 
In cancer therapeutics, several new targets such as enzymes and proteins 
are constantly involved in critical cellular processes including DNA 
replication and cell division. DNA topoisomerase I (topo I) is protein that 
catalyzes topological problems as well as nuclear processes such as DNA 
replication, transcription, repair and chromatin by un-winding duplex DNA 
[52]. Topoisomerase (topo I) cleaves one strand of supercoiled plasmid DNA 
pBR322 as well as a phosphodiester bond to the resultant unwound relaxed 
DNA [53]. In physiological conditions, the DNA cleavage and ligation 
reactions catalyzed by the topoisomerase I are tightly coordinated and 
produces rarely detected covalent 3′- 
 
phosphorotyrosyl adduct intermediate [54]. Numerous drugs like ir-inotecan, 
topotecan and camptothecin (CPT) can inhibit topoisomerase I by blocking 
the religation step and enhancing the formation of per-sistent DNA breaks 
responsible for cell death [35]. The eﬀ ect of com-plexes 1 and 2 on the 
activity of Topo I was investigated on plasmid DNA pBR322 cleavage assay 
by agarose gel electrophoresis. The in-vestigation shows that complexes 1 
and 2 inhibit topoisomerase I in a concentration dependent manner. 
Topoisomerase inhibition assay an-ticipates a direct determination of the 
drugs eﬀ ect on the unwinding of a supercoiled duplex DNA to a nicked open 
circular and relaxed DNA. As shown in Fig. 8(a) and (b), the supercoiled 
DNA pBR322 was fully relaxed by the topo in the absence of complexes 1 
and 2 (lane 2). However, on increasing the concentration of complex 1 (0–25 
ȝM) and 2 (0–50 ȝM) respectively, the relaxed DNA (form II) were inhibited 
(lanes 3–7). Complex 1 completely inhibited Topo I and similar results were 
also observed with complex 2. The IC50 values for complexes 1 and 2 were 
found to be 7 and 35 ȝM respectively. Recently, it has been reported that 
dinuclear copper(II) complex showed inhibitory eﬀ ects on the catalytic 
activity of topoisomerase I at a concentration, ∼12.5 ȝM [55]. The complexes 
1 and 2 were found to be a better candidate in the inhibition of topoisomerase 
I as compared to some of the standard to-poisomerases I inhibitors like 
camptothecin, doxorubicin, novobiocin, etoposide [56]. 
 
 
 
3.9. Molecular Docking With DNA 
 
The orientation of molecules can direct the recognition of precise 
sequences and structures of nucleic acids which plays prominent role in the 
field of metallo pharmaceutical. The molecular docking studies have a 
noteworthy feature in demonstrating the drug-DNA interaction in the rational 
designing of drugs as well as enlighten the mechanistic insight study by 
inserting a small molecule towards the binding aﬃnity site of the DNA 
primarily in a non-covalent fashion which can easily envisages the 
interactions between the nucleic acids of DNA and the drug molecules. The 
conformation of docked complex usually assesses in terms of hydrogen 
bonding, energy and hydrophobic interaction between the DNA and complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. Eﬀ ects of diﬀ erent concentrations of 1 and 2 on the activity of DNA Topoisomerase I. 
 
 
  
 
Fig. 9. Representative docking structure of groove binding of 
the DNA with complexes 1(a) and 2 (b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The energetically favorable docked pose attained from the rigid molecular 
docking of complexes 1 and 2 with a DNA duplex of sequence 
d(CGCGAATTCGCG)2 dodecamer (PDB ID: 1BNA) was executed in order 
to foresee the binding mode along with the most minimum energy favored 
orientation (Fig. 9). The result shows that complex 2 interacts with the minor 
groove of DNA via electrostatic/hydrophobic interac-tions as illustrated in 
S13. The outcome binding energy of docked li-gand and complex 1 with 
DNA was found to be −6.4 and −8.6 kcal/ mol, respectively indicating strong 
binding propensity towards the minor groove of DNA. While complex 1 
favored major groove binding propensity dominated by electrostatic non 
covalent interaction with binding energy −8.3 kcal/mol. All the docking 
results are correlating well with the experimental binding and cleavage 
studies with DNA. 
 
3.10. Molecular Docking With Human Topoisomerase I 
 
In order to determine the mechanistic basis for the inhibitory action and to 
obtain accurate binding mode on Topo I, the complexes 1 and 2 were studied. 
The resulting docked models exhibited a dual mode of binding on Topo I due 
to conformation changes (viz, structural 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
flexibility) of the interacting complexes 1 and 2. Fig. 10 shows aromatic rings 
of complexes approaching the DNA cleavage site in the Topo I 
 –DNA complex and forming a stable complex through π–π stacking 
interactions between the purine and pyrimidine ring in the minor groove on 
the scissile strand and C112 and A113 on the non–scissile strand, parallel to 
the plane of base pairs. The aromatic (antheracene and bi-pyridine) 
chromophore fragments of the complexes also suc-cessfully forms various 
hydrophobic contacts like π–π Stacked, π -Alkyl, and π -Sulfur to the 
various amino acid of the Topo I enzyme, parti-cularly Leu 721, Lys 436 and 
Lys 721 which is considered an essential amino acid that interacts with the 
ligand in the DNA–Topo I active site. Additionally, aromatic rings facing 
perpendicularly to the plane of base pairs which strongly block the rewinding 
step of the phosphoester. Furthermore, DNA-intercalating forces were much 
more important for the ligand to the surrounding amino acids residues of the 
protein, or to the base pairs. Our molecular docking study proved the 
importance of DNA intercalating ability of 1 and 2 as well as π-alkyl and π–
π stacking hydrophobic interaction with the enzyme in the cleavage site as 
non-covalent interaction are listed in S13. This result suggests that blocking 
the religation of the G11 hydroxyl group could be the main design point 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10. Representative structure of the most populated cluster for the topoisomerase I-DNA-complexes 1(a) and 2 (b) docking. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11. Cytotoxicity profile of complex 1 and 2 at diﬀ erent concentrations, inhibitory concentration of complex 1 and 2 at which 50% of HeLa cells died is calculated to be 2.9 ± 2.13 and 28.2 ± 
4.47 ȝM respectively. 
 
for novel Topo I inhibitors. The resulting binding aﬃnity of minimum energy-
docked structure was found to be −16.0 and −14.3 kcal/mol respectively, 
revealing the potent greater binding aﬃnity between Human–DNA–Topo I 
and complex 1 as compared to complex 2, The model studies is suggestive of 
potential basis for conceivable design of novel anticancer drugs targeting 
active site of Topo I. 
 
3.11. Cytotoxic Study 
 
Cell toxicity is a common limitation in terms of development of new 
compounds into the chemotherapeutic pharmaceutical industry. Therefore, in 
this study we were motivated to check the cytotoxicity potential of newly 
synthesized complexes against human cervical car-cinoma cancer cells. The 
cell toxicity was commonly measured by MTT assay technique as a reliable 
method to determine bioactivity of the compounds. The transformation of 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to 
formazan by mitochondrial dehydrogenases serves as an indicator of cell 
viability [57]. A decrease in formazan production indicates a reduction in the 
number of meta-bolically active cells i.e. decrease in cell viability. MTT 
assay was done to test the ability of complexes 1 and 2 to inhibit cell growth 
and induce cell death in a HeLa (human cervical carcinoma) cancer cell lines 
as it constitute a highly proliferative human cancer model. The complexes 1 
and 2 and LH showed reduction in the viability of the HeLa cells in a 
concentration dependent manner at 24 h which reflects its significant potency 
as growth inhibiter and it is shown in Fig. 11 and S14. The half maximal 
inhibitory concentration (IC50) values of complex 1 (2.9 ± 0.021 ȝM), is 
lower than that of complex 2 (28.2 ± 0. 044 ȝM) and its ligand LH (71.0 ± 
0.043 ȝM). It is noteworthy that complex 1 has a better IC50 value than 
complex 2 in topoisomerase inhibition study. As compared to cisplatin, as 
well as some recently reported copper and zinc complexes, the IC50 value of 
complex 1 against HeLa cells suggests a stronger cytotoxic action of this 
complex 
 
than that of cisplatin and other complexes [58,59]. Both complexes showed 
potential cytotoxicity as compared to recently reported copper and zinc 
complxes of aminonaphthoquinone derivative [60]. Thus, complex 1 turned 
out to be a potential cytotoxic complex which war-rants a deeper investigation 
to enable it as a lead anticancer drug. 
 
3.12. Apoptosis 
 
To understand the mechanism of cell death, acridine orange/EB staining 
of HeLa cell was done. Acridine orange (AO) enters in all cells and makes the 
nuclei to appear green. If the cytoplasmic membrane integrity is lost then 
Ethidium bromide (EB) is taken up by cells and stains the nucleus red. EB 
also dominates over AO. Thus live cells have a normal green nucleus while 
early apoptotic cells have bright green nucleus with condensed or fragmented 
chromatin; late apoptotic cells having condensed and fragmented orange 
chromatin [61]. Untreated control cells having round and intact nucleus were 
stained green in Fig. 12. Control cell are live cell because integrity of cell 
membrane is maintained. In contrast, cells treated with ligand LH (65 ȝM) 
show few early and late apoptotic cells because some cell are live stained 
green some cells have taken EB showing either completely stained orange cell 
(post apoptotic) or only nucleus is stained (apoptotic). Complex 1 (2 ȝM) 
shows apoptosis only because all the cells are showing frag-mented nuclei 
stained orange. Complex 2 (25 ȝΜ) show late apoptotic cell, because EB is 
taken by whole cell stained orange. Complex 1 is more eﬀ ective than 
complex 2 because it is able to induce apoptosis in HeLa cell at lower 
concentration (2 ȝM). 
 
 
4. Conclusion 
 
In summary, homo dinuclear complexes bearing Cu(II)-Cu(II) 1 and 
Zn(II)-Zn(II) 2 units, each bridged by nitrato group and embedded se-parately 
with a 2,2′-bipyridine and biologically relevant chalcone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12. HeLa cell lines showing staining of acridine orange (green) and EtBr (red) in both control condition as well as after treatment with drug LH (65 ȝM), complex 1 (2 ȝM) complex 2 (25 ȝM). 
(For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
  
 
groups, are synthesized and characterized as penta-coordinated square 
pyramidal complexes bearing N2O3 coordination core. Their solid state X-ray 
crystallography and ESR spectra (Cu(II) complex only) support their 
structures. Both complexes are arranged in anti-syn fashion. The structure and 
photophysical properties of the complexes are supported by their DFT and 
TD-DFT calculations. The redox property of copper (II) complex 1 has been 
studied using its cyclic voltammetry. In the process of investigation, 
biological activities of the complexes, the DNA clea-vage capability of the 
complex, as well as DNA topoisomerase inhibi-tion was studied which 
demonstrated their potential antitumor activity. The Cu (II) complex cleaves 
supercoiled DNA pBR322 significantly with its preferential binding to major 
groove of DNA and it follows oxidative pathway whereas Zn(II) complex 
follows hydrolytic cleavage pathway and prefers to bind with the minor 
groove of DNA. The complex 1 also inhibits catalytic activity of 
topoisomerase I with IC50 value of 7 ȝM as compared to complex 2 with 
IC50 value of 35 ȝM. Groove binding and topoisomerase I binding aﬃnity 
with complexes 1 and 2 were also confirmed by molecular docking studies. 
The value to complex 1 is further added by the observation of its cytotoxicity 
with IC50 value of 2.9 ± 0.021 ȝΜ against cervical cancer cell lines (HeLa 
cells). The complex 2 gave IC50 value of 28.2 ± 0.044 ȝM. In the observed 
cy-totoxicity of the two metal complexes, it is found that the metal ions play a 
significant role as two complexes of similar geometry diﬀ er only in metal ion. 
An early stage cell apoptosis induced by 1 makes it again interesting and 
enable it as a future candidate of anticancer drug. 
 
 
Abbreviations 
 
bpy 2,2′-bipyridine  
ESR electron spin resonance  
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro- 
 mide  
NC nicked circular  
TD-DFT Time Dependent Density Functional Theory  
DAPI 4′,6-diamidino-2-phenylindole  
MG methyl green  
EB Ethidium bromide  
AO Acridine orange  
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Appendix A. Supplementary Data 
 
Electronic supplementary information (ESI) available. CCDC re-ference 
no. 750137, 773965 and 858620 contains the supplementary crystallographic 
data for LH, complex 1 and 2 respectively. For ESI and crystallographic data 
in CIF or other electronic format ESI-MS the complexes 1 and 2, Time-
dependent absorption spectral traces of complexes 1 and 2 recorded in 0–48 
h, Time-dependent emission spectral traces of complexes 1 and 2 recorded in 
0–48 h, the selected bond lengths (Å) and bond angles (°) for LH, complexes 
1 and 2, Helical supramolecular structure of complex, Weak interaction 
parameter for the LH, 1 and 2, Supramolecular structure of complex 2, ESR 
Spectrum of complex 1, Cyclic voltammogram of complexes 1, Ethidium 
bromide stained agarose gel (1%) of pBR322 plasmid DNA (300 ng ȝL−1) in 
the presence of complex 1 and complex 2 (20 ȝM) with diﬀ erent activators 
after 1 h of incubation, Cytotoxicity profile of LH at diﬀ erent concentrations 
are available. 
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